Bluejay Diagnostics (NASDAQ:BJDX) Posts Quarterly Earnings Results, Beats Estimates By $3,518.88 EPS

Posted by Francis Steltz on Aug 12th, 2026

Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report) announced its earnings results on Wednesday. The company reported ($1.12) earnings per share for the quarter, beating the consensus estimate of ($3,520.00) by $3,518.88, FiscalAI reports.

Bluejay Diagnostics Stock Performance

Shares of NASDAQ:BJDX traded down $0.02 during midday trading on Wednesday, reaching $1.05. 297,937 shares of the company’s stock were exchanged, compared to its average volume of 2,516,029. The company’s 50 day simple moving average is $2.31 and its two-hundred day simple moving average is $2.24. Bluejay Diagnostics has a 12 month low of $0.83 and a 12 month high of $16.68. The firm has a market capitalization of $1.08 million, a PE ratio of -0.09 and a beta of 0.89.

Insiders Place Their Bets

In related news, major shareholder Financial Lp Hrt sold 34,938 shares of the stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $1.40, for a total value of $48,913.20. Following the completion of the transaction, the insider owned 92,055 shares of the company’s stock, valued at $128,877. This represents a 27.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 6.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Bluejay Diagnostics

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC bought a new position in Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned approximately 9.15% of Bluejay Diagnostics at the end of the most recent quarter. Institutional investors own 18.47% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on BJDX. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Wednesday, June 24th. Wall Street Zen upgraded shares of Bluejay Diagnostics to a “sell” rating in a report on Saturday, July 18th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

Check Out Our Latest Stock Analysis on BJDX

Bluejay Diagnostics Company Profile

(Get Free Report)

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.